Astrazeneca PLC (NYSE:AZN) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.44 per share.
For the full year, analysts predict revenues of $ 26257.70 million, while looking forward to income of $ 1.98 per share.
Previous Quarter Performance
Astrazeneca PLC posted income for the second quarter of $ 0.96 per share, from the revenue of $ 6,275.00 million. The quarterly earnings swell 159.46 percent while revenues developed 7.76 percent compared with the same quarter last year.
Wall street analysts are predicting, AZN to report 2Q20 income of $ 0.44 per share from revenue of $ 6240.98 million. The bottom line results beat street analysts by $ 0.52 or 118.18 percent, at the same time, top line results outshined analysts by $ 34.02 million or 0.55 percent.
Stock Performance
Shares of Astrazeneca PLC traded up $ 3.34 or 6.46 percent on Wednesday, reaching $ 55.04 with volume of 7.33 million shares. Astrazeneca PLC has traded high as $ 55.37 and has cracked $ 53.92 on the downward trend
The closing price of $ 55.04, representing a 43.02 % increase from the 52 week low of $ 36.15 and a 20.39 % decrease over the 52 week high of $ 64.94.
The company has a market capital of $ 143.76 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Stock Dividend Announcement
The board of directors has authorized semi-annual dividend of $ 0.45 per share on July 30, 2020. The dividend were payable on September 14, 2020 to holders of record as of the close of business on August 14, 2020 and ex-dividend date on August 13, 2020.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The companys marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.
